|
Name |
curvularide B
|
Molecular Formula | C18H33NO4 | |
IUPAC Name* |
(E)-3-[(2R)-3-[(2S,4R)-4-hydroxyhexan-2-yl]-2-methyloxiran-2-yl]-N-[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]prop-2-enamide
|
|
SMILES |
CC[C@H](C)[C@@H](CO)NC(=O)/C=C/[C@@]1(C(O1)[C@@H](C)C[C@@H](CC)O)C
|
|
InChI |
InChI=1S/C18H33NO4/c1-6-12(3)15(11-20)19-16(22)8-9-18(5)17(23-18)13(4)10-14(21)7-2/h8-9,12-15,17,20-21H,6-7,10-11H2,1-5H3,(H,19,22)/b9-8+/t12-,13-,14+,15+,17?,18+/m0/s1
|
|
InChIKey |
KQYIQWJQJFWGMP-HDGBDWCISA-N
|
|
Synonyms |
curvularide B; (E)-N-[(1S,2S)-1-(hydroxymethyl)-2-methyl-butyl]-3-[(2R)-3-[(1S,3R)-3-hydroxy-1-methyl-pentyl]-2-methyl-oxiran-2-yl]prop-2-enamide; 3-{(2R)-3-[(2S,4R)-4-Hydroxyhexan-2-yl]-2-methyloxiran-2-yl}-N-[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]prop-2-enamide
|
|
CAS | NA | |
PubChem CID | 71588984 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 327.5 | ALogp: | 2.2 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 82.1 | Aromatic Rings: | 1 |
Heavy Atoms: | 23 | QED Weighted: | 0.425 |
Caco-2 Permeability: | -4.816 | MDCK Permeability: | 0.00002180 |
Pgp-inhibitor: | 0.031 | Pgp-substrate: | 0.889 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.472 | Plasma Protein Binding (PPB): | 47.72% |
Volume Distribution (VD): | 0.863 | Fu: | 42.54% |
CYP1A2-inhibitor: | 0.025 | CYP1A2-substrate: | 0.34 |
CYP2C19-inhibitor: | 0.044 | CYP2C19-substrate: | 0.816 |
CYP2C9-inhibitor: | 0.033 | CYP2C9-substrate: | 0.126 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.204 |
CYP3A4-inhibitor: | 0.187 | CYP3A4-substrate: | 0.376 |
Clearance (CL): | 8.672 | Half-life (T1/2): | 0.644 |
hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.429 |
Drug-inuced Liver Injury (DILI): | 0.245 | AMES Toxicity: | 0.35 |
Rat Oral Acute Toxicity: | 0.038 | Maximum Recommended Daily Dose: | 0.202 |
Skin Sensitization: | 0.605 | Carcinogencity: | 0.769 |
Eye Corrosion: | 0.04 | Eye Irritation: | 0.677 |
Respiratory Toxicity: | 0.943 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003222 | 0.718 | D08QME | 0.207 | ||||
ENC002712 | 0.577 | D03KIA | 0.190 | ||||
ENC002713 | 0.556 | D0HD9K | 0.189 | ||||
ENC003711 | 0.435 | D0RA5Q | 0.188 | ||||
ENC003234 | 0.400 | D05PLH | 0.187 | ||||
ENC004454 | 0.311 | D00WUF | 0.187 | ||||
ENC002873 | 0.296 | D0P2IW | 0.186 | ||||
ENC003253 | 0.274 | D0N3NO | 0.184 | ||||
ENC003129 | 0.270 | D02RQU | 0.183 | ||||
ENC001171 | 0.264 | D03XTC | 0.178 |